prognostic information in some settings. There is evidence for significant heritability of ECG-LVH. We conducted a large-scale gene-centric association analysis of 4 commonly measured indices of ECG-LVH. Methods and Results-We calculated the Sokolow-Lyon index, Cornell product, 12-lead QRS voltage sum, and 12-lead QRS voltage product in 10 256 individuals from 3 population-based cohorts and typed their DNA using a customized gene array (the Illumina HumanCVD BeadChip 50K array), containing 49 094 genetic variants in Ϸ2100 genes of cardiovascular relevance. We followed-up promising associations in 11 777 additional individuals. We identified and replicated 4 loci associated with ECG-LVH indices: 3p22.2 (SCN5A, rs6797133, Pϭ1.22ϫ10
I ncreased left ventricular (LV) mass (left ventricular hypertrophy [LVH]
) is a common manifestation of preclinical cardiovascular disease that predicts cardiovascular morbidity and mortality in some settings. 1 LVH occurs in a wide range of disorders, including hypertension, obesity, and valvular heart disease. Its clinical relevance is further underscored by the finding that reduction of LVH with antihypertensive treatment is associated with decreased risk of cardiovascular events independent of treatment modality and degree of blood pressure lowering. 2 Several noninvasive measures of LVH have been developed, including those based on echocardiography and magnetic resonance imaging; however, worldwide, the most commonly applied assessments clinically are based on the routinely recorded 12-lead ECG. These include calculations of the Sokolow-Lyon index, the Cornell product, the 12-lead QRS voltage sum, and the 12-lead QRS voltage product (Table 1) . [3] [4] [5] [6] ECG-indexed LVH and echocardiographically determined LVH (echo-LVH) predict cardiovascular mortality independently of each other, 7 suggesting that they capture somewhat different information on cardiac status.
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Development of LVH in the context of predisposing conditions shows considerable inter-individual variability. 1, 2, 7 This is at least partly because of genetic factors. ECG indices of LVH have been shown to have significant heritability (Sokolow-Lyon index Ϸ40%, Cornell product Ϸ23%) that is at least similar if not higher than that for echo-LVH (Ϸ26%). 8 A previous linkage analysis found suggestive evidence for loci on chromosomes 10q23.1 (LOD 2.21) for the SokolowLyon index, on 17p13.3 (LOD 2.67) for the Cornell product, and on 12q14.1 (LOD 2.19) for echo-LVH. 9 Recently, a meta-analysis (nϭ12 612) of genome-wide association studies of echo-LV mass and LV wall thickness did not find any definite associations with either of these traits. 10 To gain a better understanding of the genetic determinants of ECG-LVH, we undertook a large-scale cardiovascular gene-centric analysis of the Sokolow-Lyon index, Cornell product, 12-lead QRS voltage sum, and 12-lead QRS voltage product in 3 population-based cohorts, followed by replication of promising signals in 3 further sample sets. For the discovery stage, we used a recently developed customized array, the Illumina HumanCVD BeadChip 50K array, which provides extensive coverage of Ϸ2100 genes/loci of highest relevance to the cardiovascular system. 11
Materials and Methods

Study Cohorts
For the discovery stage, we studied individuals from 3 populationbased cohorts: The British Women's Heart and Health Study (BWHHS, nϭ3443), 12 the Genetic Regulation of Arterial Pressure of Humans In the Community (GRAPHIC) Study (nϭ2024), 13 and the Whitehall II Study (WHII) (nϭ5059). 14 The replication cohorts comprised individuals from the British Regional Heart Study (BRHS) (nϭ3519), 15 the BRItish Genetics of HyperTension (BRIGHT) Study (nϭ1198) 16 and the Prevention of REnal and Vascular ENdstage Disease (PREVEND) Study (nϭ7060). 17 See Table 2 for summary characteristics of the cohorts, and find further details on recruitment and assessment in the online-only Supplemental Materials.
Analysis in both the discovery and replication cohorts was restricted to subjects of European white descent. Local research ethics committees gave ethics approval for all of the studies, and participants provided written informed consent.
Electrocardiographic Measures of Left Ventricular Hypertrophy
For the BWHHS, GRAPHIC, WII, BRHS, and BRIGHT studies, standard 12-lead ECGs were recorded on either Siemens 460 electrocardiographs or Burdick Eclipse or Atria models. Digital ECG data were in all cases transferred to the University of Glasgow ECG Core Laboratory based in Glasgow Royal Infirmary, and the University of Glasgow ECG analysis program analyzed all ECGs. 18 This software meets all of the required specifications in terms of measurement accuracy and is used widely in various commercial products and clinical trials. All ECGs were reviewed manually and checked for technical problems that would have interfered with analysis, and technically unsatisfactory ECGs were excluded. In PREVEND, standard 12-lead ECGs were recorded with CardioPerfect equipment (Cardio Control; currently Welch Allyn, Delft, the Netherlands) and were electronically stored and digitally analyzed using the computer program MEANS (Modular ECG ANalysis System). 19 For each ECG-LVH index, outliers more than 3 standard deviations away from the mean were excluded from the analysis. Based on the observed distribution of the phenotypic measures (online-only Supplemental Figure 1 ), analysis was done on untransformed data.
Genotyping and Quality Control
The discovery cohorts were all genotyped identically using the Illumina HumanCVD BeadChip 50K array. 11 Genotypes were called using the Illumina BeadStudio (v3) Genotyping Module, which uses the GenCall software application to automatically cluster, call genotypes, and assign confidence scores. Samples with a genotype call rate less than 90% were removed from the analysis. Single-nucleotide polymorphism (SNPs) were only included in the association analysis if they satisfied the following criteria: SNP call rate Ն0.95, minor allele frequency Ͼ1%, and Hardy-Weinberg Equilibrium probability value (P value) Ͼ1ϫ10
Ϫ04 . For replication of the SNPs taken forward from the discovery phase, genotypes were generated de novo for the PREVEND Study and BRHS using KASPAR assays (KBioscience, Hoddesdon, Herts, UK) and extracted in silico from HumanCVD 50K array data for the BRIGHT Study.
Statistical Analysis
Discovery
For the discovery cohorts, separate within-cohort linear regression analyses were performed for each ECG-LVH trait using an additive genetic model adjusting for age, sex, body mass index, and systolic blood pressure. For individuals on blood pressure-lowering medication, systolic blood pressure was adjusted by adding a constant of 15 mm Hg as recommended by Tobin et al. 20 Covariates were selected based on prior knowledge and direct evidence of their correlation with ECG-LVH indices in the 3 cohorts (online-only Supplemental Table 1 ). In GRAPHIC, additional adjustments for age 2 (because of the 2-generational structure of the cohort) and familial correlation were taken into account using generalized estimating equations with an exchangeable correlation structure.
After verifying strand alignment, a meta-analysis of the results from the 3 studies was conducted. Because Ϸ30% of SNPs passing • QRS voltage product (V ⅐ s)ϭQRS voltage sumϫQRS duration 5, 6 our replication threshold of 1ϫ10 Ϫ4 showed moderate heterogeneity (I 2 of between 40 and 70), using the DerSimonian-Laird estimator (I 2 ) for heterogeneity, 21 we chose a random-effects model for our primary analysis. Use of a fixed-effects model did not identify any additional loci passing this threshold. Bonferroni correction for 33 950 SNPs that passed quality control in all 3 discovery cohorts is 1.47ϫ10 Ϫ6 ; however, given the fact that the prior odds of association in this cardiovascular gene-centric study are likely to be higher than for a whole-genome array, and the opportunity to eliminate false-positives at the replication stage, the discovery threshold was relaxed to 1ϫ10 Ϫ4 to take SNPs forward for replication. Using the Q value package in R (v1.26.0) (http://cran.r-project.org/web/ packages/qvalue/index.html), this gave an estimated false discovery rate of of 26.3%. Where multiple SNPs within the same locus reached significance, we selected the lead SNP from each locus to take forward for replication. At each locus, conditional association analyses were performed, whereby the lead SNP was added to the model as a covariate to identify any additional independent signals.
Replication
Linear regression analysis was carried out in each of the 3 replication cohorts for the selected SNPs with the trait with which they were significantly associated in the discovery stage. Adjustments were again made for age, sex, body mass index, and corrected systolic blood pressure. A meta-analysis of the results from the replication studies was done using the same method as in the discovery phase. A Bonferroni correction for the number of (12 SNPs) taken to replication was applied to the standard 0.05 threshold, giving a significance threshold of Pϭ4.17ϫ10
Ϫ3
. See the online-only Supplemental Materials for details of how the power of the replication study was calculated.
Calculation of Heritability of ECG-LVH Traits
We took advantage of the family structure of the GRAPHIC Study 13 to calculate heritability of the ECG-LVH traits. Heritability estimates were calculated using variance component analyses as implemented in SOLAR version 4.2.7 22 and adjusted for age and sex (model 1) and then for several other covariates (model 2), as described in the online-only Supplemental Materials.
Calculation of Variance Explained
A univariate linear regression was used to determine the amount of trait variation explained by the SNP of interest within each study. In GRAPHIC, only the parental generation was used to calculate the r 2 value. To calculate the combined variance explained by each of the 4 replicated SNPs across all 3 studies, we used the metacor package (v1.0.1) (http://cran.r-project.org/web/packages/metacor/index.html) in R v2.11.1, (http://cran.r-project.org/) which implements the DerSimonian-Laird 21 random-effect meta-analytic approach with correlation coefficients as effect sizes.
Top-Decile Analysis
We examined the effect of our 4 significant SNPs on the odds of being in the top decile of their respective trait, QRS voltage sum (rs2290893, rs2292462, rs4966014), and Cornell product (rs6797133). This was performed in each discovery study individually using logistic regression, and the results were meta-analyzed using random effects. (Fixed-effects analysis provided similar results.) In addition, for QRS voltage sum, a risk score was generated as the sum of risk alleles for each individual, assuming an additive effect, of the 3 SNPs significantly associated with this trait. Using the 0 to 2 risk allele-carrying subjects as the reference group, the odds of BMI indicates body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; V, microvolts; V ⅐ s, microvolt seconds.
being in the top decile of the QRS voltage sum were calculated for subjects carrying 3, 4, 5, or 6 risk alleles.
Functional Analysis
To identify potential functional variants in the 4 novel ECG-LVH loci, we used the "SNAP" tool of the Broad Institute (http://www.broadinstitute.org/mpg/snap/) to identify other SNPs correlated by either r 2 (Ͼ0.5) or DЈ (Ͼ 0.8) to the lead SNPs. The list of SNPs thus generated was then applied to the "SNP Function Portal" of Brain Array (http://brainarray.mbni.med.umich.edu/Brainarray/ Database/SearchSNP/snpfunc.aspx) to assess for potential functionality.
We also analyzed eQTLs (expression quantitative trait loci) related to the 4 novel ECG-LVH loci in monocyte transcriptomes from 395 healthy blood donors and 363 patients with premature myocardial infarction, assembled by the Cardiogenics consortium. Find further details of this analysis in the online-only Supplemental Materials.
Analysis of ECG-LVH Associated Variants With Echo-LV Mass
Association statistics for echo-LV mass were obtained from the genome-wide meta-analysis carried out by the ECHOGEN Consortium. 10 The discovery analysis for this study combined data from 5 cohorts (Cardiovascular Health Study, Framingham Heart Study, Rotterdam Study, Multinational Monitoring of Trends and Determinants in Cardiovascular Disease study [MONICA-KORA], and Gutenberg Heart Study) with total sample size of 12 612. Find further details in the online-only Supplemental Materials.
Results
Discovery Stage
The discovery sample comprised 10 526 individuals in total: 3443 from BWHHS, 2024 from GRAPHIC, and 5059 from the WHII Study. Cohort characteristics are shown in Table 2 . The distributions of the ECG measures were very similar in each cohort (online-only Supplemental Figure 1 ). There were strong intra-individual correlations between the 12-lead QRS voltage sum and the 12-lead QRS voltage product, moderate correlations between either the Cornell product or Sokolow-Lyon index and the 12-lead QRS indices, and no correlation between the Cornell product and the Sokolow-Lyon index (online-only Supplemental Table 1 ). Analysis of familial correlations in the GRAPHIC study confirmed the significant heritability of each of the traits, ranging between 31% and 44% (online-only Supplemental Table 2 ). The number of SNPs surviving quality control and taken forward for association analysis in the discovery phase ranged between 34 321 and 36 381 for the 3 cohorts (online-only Supplemental Table 3 ). The quantile-quantile plots for each cohort are shown in online-only Supplemental Figure 2 . The genomic inflation factors ranged between 1.000 and 1.079, suggesting no substantial population stratification.
A total of 47 SNPs in 12 loci passed the discovery meta-analysis P value threshold of Ͻ1ϫ10 Ϫ4 for replication. Conditional analysis of the lead SNPs in each locus did not identify any additional independent effects, and these were therefore selected for replication. These comprised 6 SNPs selected on the basis of an association with the 12-lead QRS voltage sum, 1 with the 12-lead QRS voltage product, 4 with the Cornell product, and 1 with the Sokolow-Lyon index (Table 3) . Replication was undertaken in 3 additional cohorts (PREVEND, BRHS, and BRIGHT), totaling 11 777 individuals. Table 2 provides details of the replication cohorts.
Replication Stage
Of the 12 SNPs taken into replication, 4 showed evidence of significant association for their specific trait in the replication studies after allowing for the number of tests (PϽ4.17ϫ10 Ϫ3 ) ( Table 3 ). These were variants in the PTGES3 (12q13.3), NMB (15q25.2), and IGF1R (15q26.3) loci for the 12-lead QRS voltage sum and the SCN5A (3p22.2) locus for the Cornell product. Meta-analysis of the combined discovery and replication data gave probability values of 3.74ϫ10
Ϫ7 and 1.22ϫ10 Ϫ7 for the lead SNPs in the PTGES3 (rs2290893), NMB (rs2292462), IGF1R (rs4966014), and SCN5A (rs6797133) loci, respectively (Figure 1) . Table 3 shows summary findings in the replication samples for the SNPs that did not replicate, and online-only Supplemental Figure 3 shows the results for the individual studies. The replication sample had Ͼ95% power to replicate all the SNPs taken through for the effect sizes and mean minor allele frequency seen in the discovery cohorts; however, to formally assess the potential bias introduced by any "winner's curse," further power calculations were undertaken based on an adjusted discovery ␤, corrected as described by Zhong and Prentice. 23 (See the online-only Supplemental Materials.) This showed ( Table 3 ) that for several SNPs, especially those near the probability value threshold used to select SNPs for replication, power for replication may have been very limited if the true effect sizes were actually much lower. Therefore, caution needs to be exercised in the interpretation of the nonreplication of these variants. Figure 2 shows the regional association plots in the combined discovery samples for the 4 replicated loci, with the lead SNP highlighted. For each locus, the chromosomal segment with SNPs showing a high (r 2 Ͼ 0.8) linkage disequilibrium (LD) with the lead SNP is also marked (vertical lines). For the SCN5A and IGF1R loci, the signal was localized within the corresponding gene ( Figure 2 , A and D); however, for the PTGES3 and NMB loci, the region containing SNPs in strong LD with the lead SNP spanned several genes (Figure 2 , B and C).
Functional Analysis
By cross-referencing to HapMap3 data, we examined whether there were any putative functional variants within each locus that were in LD with the lead SNPs. At the NMB locus, the lead SNP (rs2292462) was in LD (r 2 ϭ0.476, DЈϭ1.0) with a nonsynonymous SNP (rs1051168, proline to threonine), 234 base pairs away that had an association signal (Pϭ4.3ϫ10 Ϫ5 ) with the QRS voltage sum in the discovery meta-analysis comparable with that of the lead SNP.
We also examined whether the lead SNP at each locus was independently associated with expression of genes in that locus in monocytes. The online-only Supplemental Table 4 presents full findings. There was a strong association of rs2958155, a perfect surrogate for rs2290893 in the PTGES3 locus, with expression level of RBMS2 (Pϭ1.85ϫ10
Ϫ37
) in a codominant fashion with the minor allele, associated with a higher level of RBMS2 expression and the variant explaining 17.9% of the total variance of RBMS2 transcript level. SNP rs2958155 was also more modestly associated with the expression of PRIM1 (Pϭ2.59ϫ10
Ϫ8
). In the NMB locus, rs2292462 showed an association with expression of WDR73 (Pϭ9.15ϫ10
Ϫ9
) and ) are shown in bold.
CHR indicates chromosome; N, total No. of subjects analyzed in the discovery cohorts for the specific SNP; Mean MAF, mean of minor allele frequency. *Power estimate for replication calculated on the basis on an adjusted discovery ␤ corrected for possible "winner's curse" as described by Zhong and Prentice. 23 with NMB itself (Pϭ9.27ϫ10
Ϫ11
), although it should be noted that whereas RBMS2, PRIM1, and WDR73 had abundant transcripts within monocytes, expression level of NMB was at the lower limit of detection on the gene expression array (onlineonly Supplemental Table 4 ). Association of the minor allele of rs2290893 (PTGES3 locus) with higher RBMS2 expression was also seen in fibroblasts in 2 publicly available eQTL datasets. (See the online-only Supplemental Materials.)
Variance Explained and Top-Decile Analysis
The amount of trait variance explained by each of the 4 novel loci was Ͻ1% (online-only Supplemental Table 5 ). To investigate the potential clinical relevance of our findings, we examined the extent to which carriage of a trait-raising allele increased the chance of being in the top 10% of individuals for that trait. This showed that this risk was increased by between 8% (rs6797133, SCN5A) and 19% (rs2292462, NMB) per allele copy (Figure 3) . To assess the combined effects of the 3 loci (PTGES3, NMB, and IGF1R) affecting the QRS voltage sum, we compared the odds ratio of being in the top decile for the trait for those carrying 6 trait-raising alleles versus those carrying 0 to 2 alleles. This showed a 1.60-fold (95% CI: 1.20 to 2.29) increased likelihood of being in the top decile (Figure 4 ).
ECG-LVH Variants and Echo-LV Mass
To assess if any of our replicated variants associated with echo-LV mass, we used data from the genome-wide association meta-analysis of this trait reported by the ECHOGEN Consortium. We found no evidence for association of any of the variants with echo-LV mass (online-only Supplemental Table 6 ).
Previous Candidate Genes and ECG-LVH
Previous studies have suggested an association of specific variants in genes of the renin-angiotensin system cascade and LVH, notably the A1166C variant in the angiotensin II receptor type 1 gene, the M235T polymorphism in angio- (IGF1R) with QRS sum. In each panel, associations are reported by study separately for the discovery and replication cohorts, together with pooled estimates for discovery, replication, and overall. ␤ coefficients (with 95% confidence intervals) describe the per-allele effect of the minor allele of the SNP for the trait shown. A negative ␤ indicates that the trait had a lower value in those carrying the minor allele. The I 2 value shown in the bottom left hand for each panel is the heterogeneity index for results in the meta-analysis of all studies.
tensinogen, the insertion/deletion polymorphism in the angiotensin-converting enzyme gene, and the Ϫ344 C/T polymorphism in the CYP11B2 gene. We found no evidence that these variants were associated with ECG-LVH traits in our study (online-only Supplemental Table 7 ). We also analyzed whether variants in other genes and pathways linked to development of LVH showed any association with ECG-LVH traits. Here we found nominal associations with variants in several genes (online-only Supplemental Table 8 ). Although the level of significance achieved for these variants in the context of the large number of SNPs examined cannot exclude the possibility that many of these associations are false-positives, their location within genes known to be involved in LVH, indicates that further analysis may be warranted.
Discussion
In this study, we confirm the significant heritability of ECG indices of LVH and report the first genetic variants robustly associated with some of these indices, providing novel insights into the determinants of this widely assessed cardiovascular trait. We further show that these variants do not associate with echo-LV mass, suggesting that these phenotypes measure somewhat distinct aspects of cardiac biology.
The association of variants in IGF1R with ECG-LVH is consistent with current understanding of the role of the insulin-like growth factor pathway in the heart, where it has been linked to inhibition of cardiac muscle growth through myostatin. 24 Mutations in SCN5A (which encodes the sodium-channel, voltage-gated, type V, ␣-subunit) cause long QT syndrome, and common variants in SCN5A and the adjacent and functionally related gene SCN10A (Figure 2A ) have been associated with 2 other ECG parameters (PR interval and QRS duration). 25, 26 Our finding of an association of variants in SCN5A with an ECG marker of LVH suggests that the SCN family of genes may influence several aspects of cardiac electrophysiology, possibly through an effect on myocyte size. The likely causal gene at the other 2 loci, PTGES3 and NMB, is less clear. PTGES3 (also known as p23 or TERT-binding protein) interacts with the telomerase reverse transcriptase (TERT) protein, which has been shown to promote hypertrophy in cultured cardiomyocytes 27 ; however, at this locus, we also observed a strong eQTL in monocytes and fibroblasts of the lead SNP with expression of RBMS2 (RNA-binding motif protein, single-stranded interacting protein, 2) and a modest association with expression of PRIM1 (primase polypeptide 1) in monocytes. RBMS2 belongs to a family of proteins that bind single-stranded DNA and RNA and that have been implicated in diverse functions such as DNA replication, gene transcription, cell cycle progression, and apoptosis, 28 although PRIM1 is involved in DNA replication. 29 At the NMB locus, we also observed modest eQTL associations in monocytes of the lead SNP with expression of NMB and WDR73. Furthermore, the lead SNP is in LD (r 2 ϭ0.476, DЈϭ1.0) with a nonsynonymous coding SNP in NMB, which codes for neuromedin B, the mammalian homologue of bombesin-like peptide. This variant has previously been associated with eating disorders and obesity. 30 Although there are no previous data directly linking neuromedin B to cardiac structure, it is involved in angiogenesis. 31 There are also data linking neuromedin B with PTK2 (protein tyrosine kinase 2) and Ca 2ϩ levels. 32 Interference of PTK2 mRNA by siRNA reverses load-induced ventricular hypertrophy in mice. As with any study of this type, the association and eQTL findings provide a first step toward identifying and studying the functionality of candidate genes in the associated region. Also, although the SNPs in MYOZ2 (myozenin 2) and TTN (titin) did not pass the criteria for replication (Table  2) , they showed suggestive evidence for association in the replication studies, given that both genes associated with hypertrophic cardiomyopathy 33, 34 and warrant follow-up.
Interestingly, the loci that we discovered here to be associated with ECG indices of LVH did not show evidence of association with echo-derived LV mass in the large meta-analysis by the ECHOGEN Consortium 10 (online-only Supplemental Table 6 ). This may seem paradoxical, and the lack of association of our loci with echo-derived LV mass may be because of chance; however, several observations indicate that the two may reflect different biological processes. The ECG measures the algebraic sum of the action potentials of myocardial fibers. Therefore, the ECG changes in cardiac hypertrophy reflect the electric remodeling of the action potential of the cardiac myofibers, which is measured in voltage and time. 35 By contrast, the echocardiogram captures anatomic remodeling of the myofibers, fibroblasts, other interstitial changes (such as inflammation), and the cardiac chambers of the heart. This is reflected in the poor correlation between ECG and echo measures of LVH in several clinical contexts. 36, 37 More direct evidence that they may be genetically different comes from assessment of ECG-LVH indices and echo-LV mass in the same families showing greater heritability for the ECG indices 8 and distinct putative loci on linkage mapping. 9 Finally, ECG and echo measures of LVH provide independent prognostic information in population studies. 7 This observation underscores the importance and relevance of identifying genetic determinants of both traits.
Consistent with variants identified for other complex quantitative traits, the amount of trait variance by each of the identified loci was low (Ͻ1%). Carriage of the trait-raising allele at each of the locus was associated with between an 8% and 19% higher probability of lying in the top 10% of the population for that trait. The effect of the 3 loci affecting QRS voltage sum was additive. Individuals carrying all 6 trait-raising alleles for these loci (Ϸ6.1% of the population) had a 1.60-fold (95% CI: 1.23 to 2.29) increased probability of lying in the top decile for QRS voltage sum compared with those carrying 0 to 2 alleles. Whether these differences impact on the cardiovascular risk associated with ECG-LVH will require further evaluation in largescale population samples.
Limitations
Our findings need to be considered in the context of some limitations of the study. The HumanCVD BeadChip 50K array contains only about 10% of all genes in the human genome with a known or suspected cardiovascular function. 11 Although providing a cost-effective analysis of variants in these genes, a significant limitation is that it does not provide full genome coverage, and we may have missed several other variants with similar or indeed greater effects than those identified. Indeed, even within the genes studied, we may have missed significant associations (for example, in those genes shown in the online-only Supplemental Table 8 ), given the threshold used for taking variants forward for replication and the power of our study. Larger and more comprehensive studies will be required to identify more loci associated with ECG-LVH traits and explain a larger proportion of their variances. Furthermore, although eQTL analysis can help to prioritize genes for further study in a locus, eQTLs can be tissue-specific, and especially because we examined peripheral rather than cardiac cells, caution needs to be exercised in the interpretation of these findings and their relevance to the observed associations.
Notwithstanding these limitations, we report the identification and replication of 4 novel loci associated with ECG indices of LVH. The findings provide new insights into the genetic influences on a routinely recorded clinically relevant cardiovascular trait with important prognostic consequences, which may help to direct research into possible therapeutic targets.
